Flush with $126M raise, Tessa Therapeutics woos new CEO from Takeda
After some repositioning — and a $126 million financing round to take it down that direction — Singapore’s Tessa Therapeutics has found a new captain to steer the ship.
Thomas Willemsen is jumping from Takeda, where he was most recently SVP, Asia-Pacific, to spearhead Tessa’s drive to develop new CAR-T therapies, including both autologous and off-the-shelf ones.
As president and CEO, Willemsen will be in charge of “corporate, business and development strategy,” the company added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.